Amplia Therapeutics Ltd has released a press release.
Positive ACCENT Trial Topline Data Released
Filed with ASX ·
6ix hasn’t read this filing yet.
Amplia Therapeutics Ltd. on 6ix
In the deck
Earlier from Amplia Therapeutics
- Capital Raising Presentation
- Amplia announces A$25m Placement and Launches A$2.5m SPP
- Second Complete Response in ACCENT Pancreatic Cancer Trial
- Pathological complete response recorded in patient from ACCENT cancer trial
- Pathological Complete Response in Pancreatic Cancer Trial
Later from Amplia Therapeutics
- Amplia Share Purchase Plan Raises $2.65 Million
- First patient dosed in new pancreatic cancer trial
- Amplia Receives R&D Tax Rebate Totalling $3.77 Million
- Positive Response from US FDA to Amplia's Type D Meeting
- Half Yearly Report and Accounts
Follow Amplia Therapeutics into a list and get an email when it puts out news.
Follow Amplia Therapeutics